BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Regulatory & Policy
Orforglipron (Foundayo) Receives MHRA Authorisation: What the UK's First Oral Small-Molecule GLP-1 Approval Means for Research and Procurement
The MHRA authorised orforglipron (Foundayo) on 10 August 2026, making the UK the first country in Europe to approve the once-daily oral GLP-1 receptor agonist for weight management and type 2 diabetes. A NICE appraisal is expected by 18 November 2026, meaning NHS access remains a 2027 prospect at the earliest. Simultaneously, the FDA is moving to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, closing the last large-scale compounding pathway in the…
07 Sep 2026
Regulatory & Policy
FDA Publishes 17 Revised Draft Product-Specific Guidances for Generic Peptides: What the New Testing Standards Mean
On 28 July 2026, the FDA released revised draft product-specific guidances for 17 injectable peptide products, including semaglutide, tirzepatide, liraglutide, and teriparatide, setting updated standards for bioequivalence, impurity thresholds, and biological activity assessment. The comment window closes 28 September 2026, making this an active regulatory moment for developers and procurement teams alike.
25 Aug 2026
Regulatory & Policy
FDA's Proposed 503B Exclusion of Compounded GLP-1s: What the NPRM Means, Where the Rule Stands, and What Research Suppliers Need to Know
The FDA's April 2026 notice of proposed rulemaking would permanently bar 503B outsourcing facilities from bulk-compounding semaglutide, tirzepatide, and liraglutide. The public comment period has closed and a final rule is pending — a development that stands in sharp contrast to the July PCAC votes favouring expanded access to non-GLP-1 peptides.
21 Aug 2026
Regulatory & Policy
Louisiana's Act 374: The First US State Law Shielding Peptide Prescribers — What It Means for the Regulatory Landscape
Louisiana's Senate Bill 253, now Act 374, came into force on 1 August 2026, becoming the first enacted US state statute to bar professional licensing boards from preventing qualified prescribers from offering patients peptides sourced from compliant 503A or 503B facilities. The law is a tangible downstream consequence of the MAHA-influenced federal reclassification drive and illustrates the patchwork state-level dynamic that shapes peptide supply chains reaching UK research institutions.
15 Aug 2026
Regulatory & Policy
FDA's 503B GLP-1 Exclusion Proposal: Comment Period Closed, Final Determination Pending — What Research Procurement Teams Should Know
The FDA's proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List has passed its public comment deadline. With the agency now reviewing submissions before issuing a final determination, research-procurement professionals face a narrowing window for sourcing compounded GLP-1 reference material through regulated large-scale channels.
10 Aug 2026
Regulatory & Policy
PCAC July 2026: Six Peptides Cleared, FDA Staff Overruled — What the Vote Results Mean for Research Procurement
The FDA's Pharmacy Compounding Advisory Committee voted on 23–24 July 2026 to recommend six of seven peptides — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for the Section 503A Bulks List, overriding its own career scientists on every favourable decision. Emideltide was the sole rejection. Formal rulemaking now begins, and none of the six can be legally compounded until that process concludes — a timeline that may extend to 2027 or 2028.
06 Aug 2026
Regulatory & Policy
The Five Peptides Heading to PCAC Before February 2027 — and Why Analysts Consider Them a Harder Case Than July's Slate
With the July PCAC votes now concluded, attention turns to the five peptides scheduled for a follow-on Pharmacy Compounding Advisory Committee review before the end of February 2027: injectable GHK-Cu, Cathelicidin (LL-37), Dihexa acetate, Melanotan II, and PEG-MGF. Each carries a more complex evidentiary or safety profile than its July predecessors, and none yet has a clear 503A compounding pathway.
03 Aug 2026
Regulatory & Policy
FDA's 503B Bulks List Comment Period Closes Today on GLP-1 Compounding Ban — What Comes Next
Today, 30 July 2026, marks the final day for public comments on the FDA's proposal to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. Once the docket closes, the agency will move toward a final determination that would strip 503B outsourcing facilities of the last legal pathway for large-scale GLP-1 compounding — with direct consequences for research procurement and the broader peptide supply chain.
30 Jul 2026
Regulatory & Policy
PCAC Two-Day Verdict: Six of Seven Peptides Recommended, Emideltide Rejected — and What the Rulemaking Path Means for Research Access
The FDA's Pharmacy Compounding Advisory Committee concluded its two-day July 2026 meeting having recommended six of the seven peptides under review for inclusion on the 503A Bulk Drug Substances List. Emideltide (DSIP) was narrowly rejected by a single vote. For research-procurement professionals, the headlines obscure the more consequential question: how long before any of this translates into a legal compounding pathway?
26 Jul 2026
Regulatory & Policy
Semax: The Russian Neuropeptide Facing Its First US Compounding Vote in Six Days — and a Hostile FDA Briefing Document
Semax, a synthetic heptapeptide approved in Russia since 2011 for neurological indications, goes before the FDA's Pharmacy Compounding Advisory Committee on 24 July 2026. FDA career scientists have already recommended against adding it — and six other peptides — to the 503A Bulks List, citing inadequate characterisation and absent human safety data. The committee's non-binding vote will nonetheless shape the regulatory trajectory for compounding access in the US and, indirectly, procurement…
25 Jul 2026
Regulatory & Policy
FDA's Two-Track Compounding Posture: Closing the Door on Approved GLP-1s While Opening a New Review for Novel Peptides
The FDA is simultaneously moving to permanently bar large-scale compounding of semaglutide, tirzepatide and liraglutide from the 503B Bulks List, while convening a Pharmacy Compounding Advisory Committee meeting on 23–24 July 2026 to consider opening regulated compounding pathways for seven novel, currently unapproved peptides. Research-procurement professionals need to understand how these two tracks interact — and what each means for sourcing decisions.
25 Jul 2026
Regulatory & Policy
PCAC Votes to Recommend All Four Day-One Peptides Over FDA Scientists' Objections — What Comes Next for the Research Supply Chain
The FDA's Pharmacy Compounding Advisory Committee voted on 23 July to recommend BPC-157, KPV, TB-500 and MOTS-c for inclusion on the 503A Bulk Drug Substances List, defying its own career scientists on every substance. Day two votes on Semax, Epitalon and Emideltide followed on 24 July. A formal rulemaking process of eight to eighteen months now stands between the recommendations and any change in legal compounding status — and five further peptides await a second PCAC meeting before the end…
25 Jul 2026